The Roles Of Academia, Rare Diseases, And Repurposing In The Development Of The Most Transformative Drugs-Reference-Cited by-同舟云学术

The Roles Of Academia, Rare Diseases, And Repurposing In The Development Of The Most Transformative Drugs

Published:2015-02 Issue:2 Volume:34 Page:286-293
ISSN:0278-2715
Container-title:Health Affairs
language:en
Short-container-title:Health Affairs

Author:

Kesselheim Aaron S.¹,Tan Yongtian Tina²,Avorn Jerry³

Affiliation:

1. Aaron S. Kesselheim ( ) is an associate professor of medicine at Harvard Medical School, in the Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham and Women’s Hospital, in Boston, Massachusetts.

2. Yongtian Tina Tan is a medical student at Harvard Medical School.

3. Jerry Avorn is a professor of medicine at Harvard Medical School and chief of the Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham and Women’s Hospital.

Publisher

Health Affairs (Project Hope)

Subject

Health Policy

Reference30 articles.

1. The productivity crisis in pharmaceutical R&D

2. A decade of change

3. Where do new medicines originate from in the EU?

4. The most transformative drugs of the past 25 years: a survey of physicians

5. Defining “Innovativeness” in Drug Development: A Systematic Review

Cited by 78 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drug Repurposing Using FDA Adverse Event Reporting System (FAERS) Database;Current Drug Targets;2024-05

2. Computational drug repurposing for viral infectious diseases: a case study on monkeypox;Briefings in Functional Genomics;2024-01-05

3. Therapeutic Benefit From New Drugs From Pharmaceutical Companies;JAMA Internal Medicine;2024-01-01

4. Biotechnology and Entrepreneurship Need Business Incubators;Curing Disease from the Ground Up;2024

5. Lab on chip for testing of repurposed drugs;Progress in Molecular Biology and Translational Science;2024